title: Safe pulmonary resection after chemotherapy and high-dose thoracic radiation.
abstract: BACKGROUND
  Pulmonary resection after high-dose thoracic irradiation is reported to be associated with a high morbidity and mortality, and has been considered to be prohibitive.
  
  
  METHODS
  We report safe pulmonary resection in 19 consecutive patients receiving neoadjuvant therapy that included greater than 59 Gy thoracic radiation. The mean thoracic radiation dose was 61.8 Gy (range 59.5-66.5) and mean age was 52 years (range 36-72 years). Cell type was adenocarcinoma (6), squamous (7), and other non-small cell lung cancer (NSCLC) (6). Sixteen of 19 patients received concurrent chemotherapy. Median time from end of treatment to surgical resection was 89 days (range 22-258 days). Surgical resection included 13 lobectomies and six pneumonectomies (four right, two left).
  
  
  RESULTS
  A complete pathologic response was seen in 8 of 19 (42%) patients. Three patients required intraoperative transfusion of blood. Mean intensive care unit stay was 2.0 days (range 1-8 days), and mean length of stay (LOS) was 8.0 days (range 3-18 days). There were four postoperative complications; one bronchopulmonary fistula, one subarachnoid-pleural fistula, and 2 patients with prolonged atelectasis. There was no incidence of acute respiratory distress syndrome (ARDS) or operative mortality.
  
  
  CONCLUSIONS
  Pulmonary resection, including pneumonectomy, after chemotherapy and high-dose thoracic radiation may be performed safely with a low rate of intraoperative and postoperative complications.
authors.affiliation: Division of Thoracic Surgery, Greenebaum Cancer Center, University of Maryland Medical Center, Baltimore 21201, USA. jsonett@surgery2.umaryland.edu
authors.forename: J R
authors.initials: JR
authors.lastname: Sonett
authors.forename: M J
authors.initials: MJ
authors.lastname: Krasna
authors.forename: M
authors.initials: M
authors.lastname: Suntharalingam
authors.forename: J
authors.initials: J
authors.lastname: Schuetz
authors.forename: L A
authors.initials: LA
authors.lastname: Doyle
authors.forename: R
authors.initials: R
authors.lastname: Lilenbaum
authors.forename: Z
authors.initials: Z
authors.lastname: Gamliel
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D000328:Adult; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007902:Length of Stay; D008175:Lung Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011013:Pneumonectomy; D011183:Postoperative Complications / Q000209:etiology / Q000401:mortality; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant; D015996:Survival Rate